Prosus India Portfolio: PharmEasy Yield Low Returns, More IPOs Expected
Global investor Prosus saw PharmEasy yield a negative internal rate of return, PayU India business revenue growth and a $500-million payout from the Swiggy initial public offering in the current financial year. It has also called out PayU, Meesho and Bluestone as potential IPO bets in the next 18 months.
The recent financial results by the investment arm of Naspers showed that from its India portfolio, PharmEasy yielded IRR of -38%, Eruditus delivered a 14% return and PayUIndia delivered a 21% return. Meesho delivered a 20% return and ElasticRun delivered a 23% return.
The firm said the revenue of PayU India business grew 12% to $237 million, with a strong growth of 25% in the total payments in value. The EBIT margin at -5% is 2 percentage points lower than the last period but showing improvement in recent months as it drives towards profitability.
“India payments is at an inflection point post the regulatory challenges that impacted growth," the company report reads. "Following the lifting of the embargo in April 2024, the business has gained momentum with over 4,000 merchants onboarded."
Swiggy IPO
Prosus revealed that it sold 10,90,96,540 shares, reducing its stake in Swiggy to below 25% on a fully diluted basis, and generated gross proceeds of approximately $500 million during the IPO.
"The IRR of our stake in Swiggy, based on the IPO price and the net proceeds of the stake we sold, was 18%. This milestone marks a significant achievement for Swiggy and reflects our continued confidence in its potential for future growth,” it said.
From January to June, Swiggy's business-to-consumer gross order value grew 24% and its adjusted Ebitda losses reduced to $85 million, compared to last year's $145 million, according to Prosus.
More IPOs To follow
Prosus has also called out PayU, Meesho and Bluestone as potential IPO candidates in the next 18 months. This is while Eruditus, Captainfresh, Mintifi, Vastu and Mensa are being seen as potential candidates in the future.
New Investments
In October 2024, the investment group acquired a 10.65% effective interest in Mintifi Pvt. for approximately $79.9 million. Mintifi is a supply-chain finance fintech company in India.
It has also acquired an 8.4% effective (7.8% fully diluted) interest for approximately $100 million in Vastu Housing Financing Corporate Ltd.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
-
You May Inherit The Business. You Must Earn Its Credibility.
Succession tests the founder's ability to share authority as much as it tests the next generation's readiness to assume it.
-
Signing Deals Is One Thing; Making Them Work Is Another | The Week In Whys
Sometimes, things don't turn out as planned. Indian companies have lost some bids to rivals, some projects won't produce until 2030.
-
FOMC Wall, PERM Suspension, Hospital Stocks | Talking Points This Week
A PERM suspension would directly affect green-card sponsorship rather than H-1B visas, so the near-term earnings impact could remain relatively limited. The key question is whether this marks a new phase in US scrutiny of Indian IT.
-
Everything, Everywhere, All At Once: Dalal Street's Week To Forget | Joining The Dots
Visa curbs, a Starlink spat and cancer drug caps: what connects this week's shocks for Indian markets
-
India Is Going Abroad For Critical Minerals. But It May Take Years To Pay Off | The Reason Why
Although India's steps are in the right direction, they remain modest compared with India's growing dependence.